Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleAllegretti JR, Kelly CR, Grinspan A, et al., 2020,
Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection
, Gastroenterology, Vol: 159, Pages: 1982-1984, ISSN: 0016-5085There has been an increase in the burden of Clostridioides difficile infection (CDI),1 especially in high-risk populations such as patients with inflammatory bowel disease (IBD).2 The prevalence of CDI in the IBD population is up to 8-fold higher than comparable controls, with increased rates of recurrence and CDI-associated mortality.3 In addition, CDI may induce an IBD flare, and worsen disease severity and clinical course.4Fecal microbiota transplantation (FMT) is a guideline recommended therapy for recurrent CDI5; however, supportive randomized trials excluded patients with IBD. In retrospective trials of patients with IBD, FMT failure rates had been reported to be approximately 25% to 30%.6 In addition, Khoruts and colleagues reported that patients with IBD and CDI were more likely to fail FMT,7 leading to further uncertainty regarding the safety and efficacy of FMT in IBD patients with concurrent CDI. Accordingly, we conducted the first prospective study examining the efficacy of FMT among patients with IBD and CDI.MethodsWe conducted an open-label, prospective, single-arm, multicenter cohort study at 4 tertiary care FMT referral centers (Brigham and Women’s Hospital, Indiana University, Brown University, and Mount Sinai Hospital; NCT03106844). Patients with a confirmed diagnosis of IBD and 2 or more confirmed CDI episodes within 12 months, including the most recent episode occurring within 3 months, were enrolled. In keeping with CDI clinical guidelines,5 polymerase chain reaction or glutamate dehydrogenase with toxin enzyme immunoassay were permitted for the qualifying CDI episode. Patients with a total or subtotal colectomy, isolated ileal or small bowel Crohn’s disease, those pregnant or breastfeeding, those treated with vancomycin or metronidazole for more than 60 days, or those who had undergone a prior FMT within 12 months were excluded. Baseline IBD and CDI data were collected. All patients underwent a single FMT via colonoscopy. Four robus
-
Journal articleCraven LJ, McIlroy JR, Mullish BH, et al., 2020,
Letter: Intestinal microbiota transfer – Updating the nomenclature to increase acceptability
, Alimentary Pharmacology and Therapeutics, Vol: 52, Pages: 1622-1623, ISSN: 0269-2813This article is linked to Lai et al paper. To view this article, visit https://doi.org/10.1111/apt.15116
-
Book chapterGhani R, Mullish BH, 2020,
Decision: Considerations for Use of Fecal Microbiota Transplantation in Special Patient Populations
, The 6 Ds of Fecal Microbiota Transplantation: A Primer from Decision to Discharge and Beyond, Editors: Allegretti, Kassam, Publisher: Slack Incorporated, ISBN: 9781630917500 -
Book chapterMullish BH, 2020,
The Role of Fecal Microbiota Transplantation in the Treatment of Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
, The 6 Ds of Fecal Microbiota Transplantation: A Primer from Decision to Discharge and Beyond, Editors: Allegretti, Kassam, Publisher: Slack Incorporated, ISBN: 9781630917500 -
Journal articleAlexander JL, Mullish BH, 2020,
A Guide to the Gut Microbiome and its Relevance to Critical Care
, British Journal of Nursing, Vol: 29, Pages: 1106-1112, ISSN: 0966-0461<jats:p> Although it is well-established that particular bacteria may cause gastroenteritis and other infections when present in the gut, it is only recently that scientists have made significant inroads into understanding the huge number of other bacteria and additional microbes that live within the gastrointestinal tract, referred to as the gut microbiome. In particular, it is now recognised that bacteria within the gut microbiome have a wide variety of roles in maintaining different aspects of human health, and that disturbances of these bacteria may potentially cause or contribute to a number of different medical conditions, including particular infections, certain cancers, and chronic conditions, including inflammatory bowel disease. Moreover, there is increasing awareness that these bacteria help determine how the body responds to medication, including antibiotics and chemotherapy. There has been growing interest in different approaches to alter the gut microbiome as a novel approach to medical therapy. This article provides an overview of the importance of the gut microbiome, with a particular focus on critical care. </jats:p>
-
Conference paperAllegretti JR, Kelly C, Grinspan AM, et al., 2020,
S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection
, Publisher: Ovid Technologies (Wolters Kluwer Health), Pages: S326-S326, ISSN: 0002-9270 -
Journal articleIaniro G, Segal JP, Mullish BH, et al., 2020,
Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders
, Future Microbiology, ISSN: 1746-0913 -
Journal articleSegal JP, Mullish BH, Quraishi MN, et al., 2020,
Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease
, Therapeutic Advances in Gastroenterology, Vol: 13, Pages: 1-14, ISSN: 1756-2848Faecal Microbiota transplantation is currently a recommended therapy for recurrent/refractory Clostridioides difficile infection. The success of FMT for CDI has led to interest in its therapeutic potential in many other disorders. The mechanisms that underpin the efficacy of FMT are not fully understood. Importantly, FMT remains a crucial treatment in managing CDI and hence understanding the mechanisms that underpin its success will be critical to improve its clinical efficacy, safety and usability. Furthermore, a deeper understanding may allow us to expose FMT’s full potential as a therapeutic tool for other disease states. This review will explore the current understanding of the mechanisms underlying the efficacy of FMT across a variety of diseases.
-
Journal articleIaniro G, Mullish BH, Kelly CR, et al., 2020,
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic
, Gut, Vol: 69, Pages: 1555-1563, ISSN: 0017-5749<jats:p>The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of<jats:italic>Clostridioides difficile</jats:italic>infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities.</jats:p>
-
Journal articleSegal JP, Mullish BH, Quraishi MN, et al., 2020,
Letter: faecal microbiota transplantation for IBS
, Alimentary Pharmacology & Therapeutics, Vol: 52, Pages: 556-557, ISSN: 0269-2813<jats:p><jats:bold>LINKED CONTENT</jats:bold></jats:p><jats:p>This article is linked to Lahtinen et al papers. To view these articles, visit<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15810">https://doi.org/10.1111/apt.15810</jats:ext-link> and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15875">https://doi.org/10.1111/apt.15875</jats:ext-link>.</jats:p>
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
General enquiries
For any enquiries about the Microbiome Network at Imperial, please contact: